Nature's Phase Zero Trials

A look into the strategic intelligence offered by polyubiquitination disorders that can give your portfolio a decisive edge

The search for validated, high-impact targets is a defining challenge for our industry. We spend billions navigating the valley of death, moving from preclinical models to human trials, often with a low probability of success. I propose a shift in perspective. We must look to a unique set of human "experiments of nature" that provide an unparalleled str…